FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377019021> ?p ?o ?g. }

• W4377019021 endingPage "101268" @default.
• W4377019021 startingPage "101268" @default.
• W4377019021 abstract "PurposeBladder preservation with trimodal therapy (TMT; maximal tumor resection followed by chemoradiation) is an effective paradigm for select patients with muscle invasive bladder cancer. We report our institutional experience of a TMT protocol using nonadaptive magnetic resonance imaging–guided radiation therapy (MRgRT) for partial bladder boost (PBB).Methods and MaterialsA retrospective analysis was performed on consecutive patients with nonmetastatic muscle invasive bladder cancer who were treated with TMT using MRgRT between 2019 and 2022. Patients underwent intensity modulated RT-based nonadaptive MRgRT PBB contoured on True fast imaging with steady state precession (FISP) images (full bladder) followed sequentially by computed tomography–based RT to the whole empty bladder and pelvic lymph nodes with concurrent chemotherapy. MRgRT treatment time, table shifts, and dosimetric parameters of target coverage and normal tissue exposure were described. Prospectively assessed acute and late genitourinary and gastrointestinal (GI) toxicity were reported. Two-year local control was assessed with Kaplan-Meier methods.ResultsSeventeen patients were identified for analysis. PBB planning target volume margins were ≤8 mm in 94% (n = 16) of cases. Dosimetric target coverage parameters were favorable and all normal tissue dose constraints were met. For MRgRT PBB fractions, median table shifts were 0.4 cm (range, 0-3.15), 0.45 cm (0-2.65), and 0.75 cm (0-4.8) in the X, Y, and Z planes, respectively. Median treatment time for MRgRT PBB fractions was 9 minutes (range, 6.9-17.4). We identified 32 out of 100 total MRgRT fractions that may have benefitted from online adaptation based on changes in organ position relative to planning target volume, predominantly because of small bowel (13/32, 41%) or rectum (8/32, 25%). Two patients discontinued RT prematurely. The incidence of highest-grade acute genitourinary toxicity was 1 to 2 (69%) and 3 (6%), whereas the incidence of acute GI toxicity was 1 to 2 (81%) and 3 (6%). There were no late grade 3 events; 17.6% had late grade 2 cystitis and none had late GI toxicity. With median follow-up of 18.2 months (95% CI, 12.4-22.5), the local control rate was 92%, and no patient has required salvage cystectomy.ConclusionsNonadaptive MRgRT PBB is feasible with favorable dosimetry and low resource utilization. Larger studies are needed to evaluate for potential benefits in toxicity and local control associated with this approach in comparison to standard treatment techniques. Bladder preservation with trimodal therapy (TMT; maximal tumor resection followed by chemoradiation) is an effective paradigm for select patients with muscle invasive bladder cancer. We report our institutional experience of a TMT protocol using nonadaptive magnetic resonance imaging–guided radiation therapy (MRgRT) for partial bladder boost (PBB). A retrospective analysis was performed on consecutive patients with nonmetastatic muscle invasive bladder cancer who were treated with TMT using MRgRT between 2019 and 2022. Patients underwent intensity modulated RT-based nonadaptive MRgRT PBB contoured on True fast imaging with steady state precession (FISP) images (full bladder) followed sequentially by computed tomography–based RT to the whole empty bladder and pelvic lymph nodes with concurrent chemotherapy. MRgRT treatment time, table shifts, and dosimetric parameters of target coverage and normal tissue exposure were described. Prospectively assessed acute and late genitourinary and gastrointestinal (GI) toxicity were reported. Two-year local control was assessed with Kaplan-Meier methods. Seventeen patients were identified for analysis. PBB planning target volume margins were ≤8 mm in 94% (n = 16) of cases. Dosimetric target coverage parameters were favorable and all normal tissue dose constraints were met. For MRgRT PBB fractions, median table shifts were 0.4 cm (range, 0-3.15), 0.45 cm (0-2.65), and 0.75 cm (0-4.8) in the X, Y, and Z planes, respectively. Median treatment time for MRgRT PBB fractions was 9 minutes (range, 6.9-17.4). We identified 32 out of 100 total MRgRT fractions that may have benefitted from online adaptation based on changes in organ position relative to planning target volume, predominantly because of small bowel (13/32, 41%) or rectum (8/32, 25%). Two patients discontinued RT prematurely. The incidence of highest-grade acute genitourinary toxicity was 1 to 2 (69%) and 3 (6%), whereas the incidence of acute GI toxicity was 1 to 2 (81%) and 3 (6%). There were no late grade 3 events; 17.6% had late grade 2 cystitis and none had late GI toxicity. With median follow-up of 18.2 months (95% CI, 12.4-22.5), the local control rate was 92%, and no patient has required salvage cystectomy. Nonadaptive MRgRT PBB is feasible with favorable dosimetry and low resource utilization. Larger studies are needed to evaluate for potential benefits in toxicity and local control associated with this approach in comparison to standard treatment techniques." @default.
• W4377019021 created "2023-05-19" @default.
• W4377019021 creator A5001987828 @default.
• W4377019021 creator A5004438347 @default.
• W4377019021 creator A5008484013 @default.
• W4377019021 creator A5019394129 @default.
• W4377019021 creator A5023853415 @default.
• W4377019021 creator A5043293845 @default.
• W4377019021 creator A5047495544 @default.
• W4377019021 creator A5054767401 @default.
• W4377019021 creator A5059162411 @default.
• W4377019021 creator A5060238737 @default.
• W4377019021 creator A5062773129 @default.
• W4377019021 creator A5065704798 @default.
• W4377019021 creator A5080324794 @default.
• W4377019021 creator A5089521164 @default.
• W4377019021 creator A5091972146 @default.
• W4377019021 date "2023-11-01" @default.
• W4377019021 modified "2023-10-14" @default.
• W4377019021 title "Trimodal Therapy Using an MR–guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer" @default.
• W4377019021 cites W1696976950 @default.
• W4377019021 cites W2000134309 @default.
• W4377019021 cites W2022952443 @default.
• W4377019021 cites W2063779292 @default.
• W4377019021 cites W2066547804 @default.
• W4377019021 cites W2117427924 @default.
• W4377019021 cites W2118328604 @default.
• W4377019021 cites W2125675894 @default.
• W4377019021 cites W2132264805 @default.
• W4377019021 cites W2164361265 @default.
• W4377019021 cites W2171486331 @default.
• W4377019021 cites W2172731163 @default.
• W4377019021 cites W2304324688 @default.
• W4377019021 cites W2606173101 @default.
• W4377019021 cites W2740627449 @default.
• W4377019021 cites W2773701834 @default.
• W4377019021 cites W2801389053 @default.
• W4377019021 cites W2946151109 @default.
• W4377019021 cites W3084585536 @default.
• W4377019021 cites W3110709574 @default.
• W4377019021 cites W3161506397 @default.
• W4377019021 cites W4206841660 @default.
• W4377019021 cites W4224992676 @default.
• W4377019021 cites W4280533968 @default.
• W4377019021 doi "https://doi.org/10.1016/j.adro.2023.101268" @default.
• W4377019021 hasPublicationYear "2023" @default.
• W4377019021 type Work @default.
• W4377019021 citedByCount "0" @default.
• W4377019021 crossrefType "journal-article" @default.
• W4377019021 hasAuthorship W4377019021A5001987828 @default.
• W4377019021 hasAuthorship W4377019021A5004438347 @default.
• W4377019021 hasAuthorship W4377019021A5008484013 @default.
• W4377019021 hasAuthorship W4377019021A5019394129 @default.
• W4377019021 hasAuthorship W4377019021A5023853415 @default.
• W4377019021 hasAuthorship W4377019021A5043293845 @default.
• W4377019021 hasAuthorship W4377019021A5047495544 @default.
• W4377019021 hasAuthorship W4377019021A5054767401 @default.
• W4377019021 hasAuthorship W4377019021A5059162411 @default.
• W4377019021 hasAuthorship W4377019021A5060238737 @default.
• W4377019021 hasAuthorship W4377019021A5062773129 @default.
• W4377019021 hasAuthorship W4377019021A5065704798 @default.
• W4377019021 hasAuthorship W4377019021A5080324794 @default.
• W4377019021 hasAuthorship W4377019021A5089521164 @default.
• W4377019021 hasAuthorship W4377019021A5091972146 @default.
• W4377019021 hasBestOaLocation W43770190211 @default.
• W4377019021 hasConcept C121608353 @default.
• W4377019021 hasConcept C126322002 @default.
• W4377019021 hasConcept C126838900 @default.
• W4377019021 hasConcept C126894567 @default.
• W4377019021 hasConcept C143409427 @default.
• W4377019021 hasConcept C2780352672 @default.
• W4377019021 hasConcept C2989005 @default.
• W4377019021 hasConcept C509974204 @default.
• W4377019021 hasConcept C71924100 @default.
• W4377019021 hasConceptScore W4377019021C121608353 @default.
• W4377019021 hasConceptScore W4377019021C126322002 @default.
• W4377019021 hasConceptScore W4377019021C126838900 @default.
• W4377019021 hasConceptScore W4377019021C126894567 @default.
• W4377019021 hasConceptScore W4377019021C143409427 @default.
• W4377019021 hasConceptScore W4377019021C2780352672 @default.
• W4377019021 hasConceptScore W4377019021C2989005 @default.
• W4377019021 hasConceptScore W4377019021C509974204 @default.
• W4377019021 hasConceptScore W4377019021C71924100 @default.
• W4377019021 hasIssue "6" @default.
• W4377019021 hasLocation W43770190211 @default.
• W4377019021 hasOpenAccess W4377019021 @default.
• W4377019021 hasPrimaryLocation W43770190211 @default.
• W4377019021 hasRelatedWork W1979321249 @default.
• W4377019021 hasRelatedWork W2049214470 @default.
• W4377019021 hasRelatedWork W2113200719 @default.
• W4377019021 hasRelatedWork W2384708512 @default.
• W4377019021 hasRelatedWork W2392413698 @default.
• W4377019021 hasRelatedWork W2415761310 @default.
• W4377019021 hasRelatedWork W2474195589 @default.
• W4377019021 hasRelatedWork W3032055452 @default.
• W4377019021 hasRelatedWork W3094186661 @default.
• W4377019021 hasRelatedWork W2118673085 @default.
• W4377019021 hasVolume "8" @default.

• next